Administration of donor T cells to bone marrow-chimeric mice with persistent host Langerhans cells, but not to mice whose Langerhans cells had been replaced, resulted in marked skin GVHD.

Patients with hematological malignancies have a risk of developing graft-versus-host disease (GVHD) following allogeneic ... targeted elimination of the donor T-cell, the putative effector ...

In addition, in mice with persistent host Langerhans cells, delayed administration of donor T cells resulted in the complete depletion of ... marked (grade 4) skin GVHD (Fig.

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...